SE9600434L - Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna - Google Patents
Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellernaInfo
- Publication number
- SE9600434L SE9600434L SE9600434A SE9600434A SE9600434L SE 9600434 L SE9600434 L SE 9600434L SE 9600434 A SE9600434 A SE 9600434A SE 9600434 A SE9600434 A SE 9600434A SE 9600434 L SE9600434 L SE 9600434L
- Authority
- SE
- Sweden
- Prior art keywords
- protein
- cells
- bacteriophages
- bacteriophage
- bacterial
- Prior art date
Links
- 241001515965 unidentified phage Species 0.000 title abstract 5
- 210000004027 cell Anatomy 0.000 title 1
- 108020001507 fusion proteins Proteins 0.000 title 1
- 102000037865 fusion proteins Human genes 0.000 title 1
- 210000004408 hybridoma Anatomy 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 208000035143 Bacterial infection Diseases 0.000 abstract 2
- 230000001580 bacterial effect Effects 0.000 abstract 2
- 208000022362 bacterial infectious disease Diseases 0.000 abstract 2
- 241001524679 Escherichia virus M13 Species 0.000 abstract 1
- 241000724791 Filamentous phage Species 0.000 abstract 1
- 206010019375 Helicobacter infections Diseases 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 abstract 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000009877 rendering Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
- C07K16/121—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Helicobacter (Campylobacter) (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2795/00—Bacteriophages
- C12N2795/00011—Details
- C12N2795/14011—Details ssDNA Bacteriophages
- C12N2795/14111—Inoviridae
- C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Priority Applications (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600434A SE506771C2 (sv) | 1996-02-06 | 1996-02-06 | Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna |
| CA002244792A CA2244792A1 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| KR10-1998-0705761A KR100459638B1 (ko) | 1996-02-06 | 1997-02-05 | 재조합파아지 |
| JP52844697A JP4015195B2 (ja) | 1996-02-06 | 1997-02-05 | 組換えファージ |
| NZ331580A NZ331580A (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| ES97902815T ES2221033T3 (es) | 1996-02-06 | 1997-02-05 | Fagos recombinantes. |
| AT97902815T ATE266091T1 (de) | 1996-02-06 | 1997-02-05 | Rekombinante phagen |
| RU98116471/13A RU2215032C2 (ru) | 1996-02-06 | 1997-02-05 | Конструкция модифицированного нитевидного бактериофага для лечения или профилактики бактериальной инфекции, модифицированный бактериофаг м13, фармкомпозиция и способ лечения бактериальной инфекции, моноклональное антитело, гибридома (вариант) |
| AU16817/97A AU712767B2 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| IL12564597A IL125645A0 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| DE69728975T DE69728975T2 (de) | 1996-02-06 | 1997-02-05 | Rekombinante phagen |
| EP97902815A EP0889955B1 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| CN97192116A CN1125174C (zh) | 1996-02-06 | 1997-02-05 | 重组噬菌体 |
| HU9901242A HUP9901242A3 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| PCT/SE1997/000172 WO1997029185A1 (en) | 1996-02-06 | 1997-02-05 | Recombinant phages |
| NO19983456A NO323359B1 (no) | 1996-02-06 | 1998-07-27 | Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel. |
| IL125645A IL125645A (en) | 1996-02-06 | 1998-08-03 | Use of a modified bacteriophage in the manufacture of a medicament |
| US09/927,420 US20020044922A1 (en) | 1996-02-06 | 2001-08-10 | Recombinant phages |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600434A SE506771C2 (sv) | 1996-02-06 | 1996-02-06 | Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE9600434D0 SE9600434D0 (sv) | 1996-02-06 |
| SE9600434L true SE9600434L (sv) | 1997-08-07 |
| SE506771C2 SE506771C2 (sv) | 1998-02-09 |
Family
ID=20401289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE9600434A SE506771C2 (sv) | 1996-02-06 | 1996-02-06 | Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0889955B1 (sv) |
| JP (1) | JP4015195B2 (sv) |
| KR (1) | KR100459638B1 (sv) |
| CN (1) | CN1125174C (sv) |
| AT (1) | ATE266091T1 (sv) |
| AU (1) | AU712767B2 (sv) |
| CA (1) | CA2244792A1 (sv) |
| DE (1) | DE69728975T2 (sv) |
| ES (1) | ES2221033T3 (sv) |
| HU (1) | HUP9901242A3 (sv) |
| IL (2) | IL125645A0 (sv) |
| NO (1) | NO323359B1 (sv) |
| NZ (1) | NZ331580A (sv) |
| RU (1) | RU2215032C2 (sv) |
| SE (1) | SE506771C2 (sv) |
| WO (1) | WO1997029185A1 (sv) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL140918A0 (en) | 1998-07-27 | 2002-02-10 | Genentech Inc | Improved transformation efficiency in phage display through modification of a coat protein |
| GB9908195D0 (en) | 1999-04-09 | 1999-06-02 | Microbiological Res Authority | Treatment of intracellular infection |
| IL146798A0 (en) | 1999-06-14 | 2002-07-25 | Genentech Inc | A structured peptide scaffold for displaying turn libraries on phage |
| EP1305038B1 (en) * | 2000-07-25 | 2005-10-05 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Bacteriophage having multiple host range |
| US6914123B2 (en) | 2001-04-17 | 2005-07-05 | Genentech, Inc. | Hairpin peptides with a novel structural motif and methods relating thereto |
| KR20040036176A (ko) * | 2002-10-23 | 2004-04-30 | (주)엘피스바이오텍 | 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법 |
| CN102296051B (zh) * | 2011-03-07 | 2014-09-17 | 江苏省农业科学院 | 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用 |
| RU2503716C1 (ru) * | 2012-09-27 | 2014-01-10 | Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) | ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ |
| GB201308745D0 (en) * | 2013-05-15 | 2013-06-26 | Imp Innovations | Bacteriophage |
| CN106198523A (zh) * | 2016-07-06 | 2016-12-07 | 哈尔滨贝贝凯尔科技发展有限公司 | 微量元素检测试纸及其制备方法 |
| WO2019070161A2 (en) | 2017-10-04 | 2019-04-11 | Opko Pharmaceuticals, Llc | ARTICLES AND METHODS FOR PERSONALIZED THERAPY OF CANCER |
| JPWO2020137421A1 (ja) * | 2018-12-27 | 2021-11-11 | 国立大学法人東海国立大学機構 | 宿主細菌特異的ナノ粒子 |
| CN109679981A (zh) * | 2019-02-21 | 2019-04-26 | 武汉大学 | 一种甲酰基肽定向进化噬菌体及其制备方法与应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| SE9304060D0 (sv) * | 1993-12-06 | 1993-12-06 | Bioinvent Int Ab | Sätt att selektera specifika bakteriofager |
-
1996
- 1996-02-06 SE SE9600434A patent/SE506771C2/sv not_active IP Right Cessation
-
1997
- 1997-02-05 AU AU16817/97A patent/AU712767B2/en not_active Ceased
- 1997-02-05 RU RU98116471/13A patent/RU2215032C2/ru not_active IP Right Cessation
- 1997-02-05 AT AT97902815T patent/ATE266091T1/de not_active IP Right Cessation
- 1997-02-05 WO PCT/SE1997/000172 patent/WO1997029185A1/en active IP Right Grant
- 1997-02-05 ES ES97902815T patent/ES2221033T3/es not_active Expired - Lifetime
- 1997-02-05 IL IL12564597A patent/IL125645A0/xx active IP Right Grant
- 1997-02-05 CN CN97192116A patent/CN1125174C/zh not_active Expired - Fee Related
- 1997-02-05 CA CA002244792A patent/CA2244792A1/en not_active Abandoned
- 1997-02-05 NZ NZ331580A patent/NZ331580A/en unknown
- 1997-02-05 DE DE69728975T patent/DE69728975T2/de not_active Expired - Fee Related
- 1997-02-05 EP EP97902815A patent/EP0889955B1/en not_active Expired - Lifetime
- 1997-02-05 JP JP52844697A patent/JP4015195B2/ja not_active Expired - Fee Related
- 1997-02-05 HU HU9901242A patent/HUP9901242A3/hu unknown
- 1997-02-05 KR KR10-1998-0705761A patent/KR100459638B1/ko not_active IP Right Cessation
-
1998
- 1998-07-27 NO NO19983456A patent/NO323359B1/no unknown
- 1998-08-03 IL IL125645A patent/IL125645A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| NZ331580A (en) | 1999-09-29 |
| EP0889955A1 (en) | 1999-01-13 |
| RU2215032C2 (ru) | 2003-10-27 |
| DE69728975T2 (de) | 2005-05-04 |
| KR100459638B1 (ko) | 2005-02-24 |
| HUP9901242A2 (hu) | 1999-07-28 |
| NO983456L (no) | 1998-10-06 |
| SE9600434D0 (sv) | 1996-02-06 |
| ATE266091T1 (de) | 2004-05-15 |
| DE69728975D1 (de) | 2004-06-09 |
| EP0889955B1 (en) | 2004-05-06 |
| CN1210558A (zh) | 1999-03-10 |
| SE506771C2 (sv) | 1998-02-09 |
| ES2221033T3 (es) | 2004-12-16 |
| NO983456D0 (no) | 1998-07-27 |
| HUP9901242A3 (en) | 2000-03-28 |
| NO323359B1 (no) | 2007-04-10 |
| JP4015195B2 (ja) | 2007-11-28 |
| IL125645A0 (en) | 1999-04-11 |
| IL125645A (en) | 2006-08-20 |
| AU712767B2 (en) | 1999-11-18 |
| KR19990082041A (ko) | 1999-11-15 |
| CN1125174C (zh) | 2003-10-22 |
| CA2244792A1 (en) | 1997-08-14 |
| AU1681797A (en) | 1997-08-28 |
| WO1997029185A1 (en) | 1997-08-14 |
| JP2000505648A (ja) | 2000-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE9600434L (sv) | Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna | |
| DE69726003D1 (de) | Immunglobulin-superfamilie domainen und fragmente mit erhöhter löslichkeit | |
| KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
| CA2274495A1 (en) | Uspa1 and uspa2 antigens of moraxella catarrhalis | |
| ATE208820T1 (de) | Humanisierte antikoerper | |
| ATE178092T1 (de) | Methode zur selektion spezifischer bakteriophagen | |
| EA199800973A1 (ru) | Полипептид белка-106 наружной мембраны moraxella catarrhalis, последовательность гена и их применение | |
| EP2067788A3 (en) | Fab fragment libraries and methods for their use | |
| ES2129487T3 (es) | Peptidos sinteticos, anticuerpos dirigidos contra ellos y su utilizacion. | |
| DK0731838T3 (da) | Bindende struktur rettet mod CA55.1 antigenet | |
| DK0720624T3 (da) | Omdirigering af antistoffer | |
| ATE477274T1 (de) | Gegen clostridium difficile gerichtete antikörper | |
| ATE353337T1 (de) | Adhesin aus heliobacter pylori, welches an blutgruppenantigene bindet | |
| RU98116471A (ru) | Рекомбинантные фаги | |
| FR2677653B1 (sv) | ||
| FR2692282B1 (fr) | Clonage du gene codant pour la proteine gp28.5 de t. gondii; fragments peptidiques issus de ladite proteine et leurs applications. | |
| CA2126182A1 (en) | Humanized antibodies reactive with gpiib/iiia | |
| DE69941051D1 (de) | Expression und charakterisierung eines hiv-1 hüllproteins, das mit einer breitreaktiven neutralisier | |
| DK0569537T3 (da) | Monoklonale antistoffer mod formodede HCV-kapperegioner og fremgangsmåder til anvendelse deraf | |
| DE69938130D1 (de) | Neue peptide | |
| DK442888D0 (da) | Slaegtspecifikt listeria-antigen identificeret ved hjaelp af monoklone antistoffer | |
| NO962827L (no) | Monoklonale antistoffer mot antigener uttrykt av hematopoietider facilitatoriske celler | |
| WO2001055353A3 (en) | Recombinant attenuation of prrsv | |
| Lachmann et al. | Generation and preliminary characterisation of monoclonal antibodies directed to glycerophospholipid: cholesterol acyltransferase (GCAT) native epitopes of Aeromonas salmonicida | |
| DK0513565T3 (da) | Monoklonale antistoffer mod plasmin-antiplasmin-komplekset, fremgangsmåde til deres fremstilling og deres anvendelse |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NUG | Patent has lapsed |